![]() | |
Clinical data | |
---|---|
Pronunciation | ə-corAM-i-dis |
Trade names | Attruby, others |
Other names | AG10 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a625013 |
License data |
|
Routes of administration | By mouth |
Drug class | Amyloidogenesis suppressant |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
PDB ligand | |
Chemical and physical data | |
Formula | C15H17FN2O3 |
Molar mass | 292.310 g·mol−1 |
3D model (JSmol) | |
| |
|
Acoramidis, sold under the brand name Attruby, is a medication used for the treatment of cardiomyopathy. [1] It is a near-complete (>90%) transthyretin stabilizer, developed to mimic the protective properties of the naturally occurring T119M mutation, [4] [5] to treat transthyretin amyloid cardiomyopathy. It is taken by mouth. [1]
The most common adverse reactions include diarrhea and upper abdominal pain. [6]
Acoramidis was approved for medical use in the United States in November 2024, [6] [7] [8] and in the European Union in February 2025. [2] [3]
Acoramidis is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. [1] [6] [9]
The most common side effects are diarrhea and abdominal pain. [10]
The efficacy and safety of acoramidis were evaluated in a multicenter, international, randomized, double-blind, placebo-controlled study in 611 adult participants with wild-type or hereditary (variant) ATTR-CM (NCT03860935). [6]
Phase I data indicated acoramidis achieved near-complete (>90%) TTR stabilization across the entire dosing interval at steady state. [11]
Phase II and the Open-Label Extension (OLE) data indicated after a median of 38 months, long-term treatment with acoramidis was generally well tolerated and resulted in a median decline in NT-proBNP levels, normalization of serum TTR, and sustained stabilization of TTR in individuals with ATTR-CM. [12]
Phase III data from ATTRibute-CM indicated acoramidis resulted in a significantly better four-step primary hierarchical outcome containing components of mortality, morbidity, and function than placebo at 30 months in participants with ATTR-CM. Adverse events were similar in the two groups. [13]
Other analyses from ATTRibute-CM indicated a 50% reduction in cumulative cardiovascular hospitalizations (CVH), a 42% reduction in all-cause mortality (ACM) and recurrent CVH, and a 3-month time-to-separation of the Kaplan Meier curves for ACM or CVH. No other treatment has demonstrated this degree of treatment effect this quickly in participants with ATTR-CM. [14] [15] [16]
In vitro data indicated acoramidis exhibits near-complete (>90%) TTR stabilization at therapeutic trough concentrations, and its TTR stabilization exceeds that of tafamidis' across a range of destabilizing TTR mutations. [17]
Acoramidis was approved for medical use in the United States in November 2024. [6] [7] [18] The approval was granted to BridgeBio Pharma. [9]
In December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Beyonttra, intended for the treatment of transthyretin amyloidosis in adults with cardiomyopathy. [2] The applicant for this medicinal product is BridgeBio Europe B.V. [2] Acoramidis was designated an orphan medicine by the EMA. [2] Acoramidis was authorized for medical use in the European Union in February 2025. [2] [3]
During development, acoramidis was known as AG10 (the Alhamadsheh-Graef molecule 10). [19]
Acoramidis is the international nonproprietary name. [20]
Acoramidis is sold under the brand names Attruby [1] [6] and Beyonttra. [2] [3]
{{cite journal}}
: CS1 maint: overridden setting (link){{cite journal}}
: CS1 maint: overridden setting (link){{cite journal}}
: CS1 maint: overridden setting (link)